• 6 results in Exploration of Targeted Anti-tumor Therapy
    Sort by
    Latest
    Open Access
    Review
    Aptamers and antibodies: rivals or allies in cancer targeted therapy?
    The goal of an efficacious cancer therapy is to specifically target diseased cells at high accuracy while sparing normal, healthy cells. Over the past three decades, immunotherapy, based on the use ...
    Lisa Agnello ... Laura Cerchia
    Published: February 28, 2021 Explor Target Antitumor Ther. 2021;2:107-121
    DOI: https://doi.org/10.37349/etat.2021.00035
    View:579
    Download:28
    Times Cited: 0
    Open Access
    Review
    Multi-omics tumor profiling technologies to develop precision medicine in multiple myeloma
    Multiple myeloma (MM), the second most common hematologic cancer, is caused by accumulation of aberrant plasma cells in the bone marrow. Its molecular causes are not fully understood and its great h...
    Sara Ovejero, Jerome Moreaux
    Published: February 28, 2021 Explor Target Antitumor Ther. 2021;2:65-106
    DOI: https://doi.org/10.37349/etat.2021.00034
    This article belongs to the special issue Off-Label Drugs and -Omics Data in Cancer Treatment
    View:913
    Download:28
    Times Cited: 0
    Open Access
    Review
    Immunotherapy in gynecological cancers
    Immunotherapy has changed the natural history of several malignancies that, a decade ago, had a very poor prognosis, such as lung cancer and melanoma. Consequently, many attempts have been done to e...
    Domenica Lorusso ... Giovanni Scambia
    Published: February 28, 2021 Explor Target Antitumor Ther. 2021;2:48-64
    DOI: https://doi.org/10.37349/etat.2021.00033
    This article belongs to the special issue Immunotherapy in Cancer Patients
    View:583
    Download:24
    Times Cited: 0
    Open Access
    Review
    Non-invasive detection of epithelial mesenchymal transition phenotype and metastatic dissemination of lung cancer by liquid biopsy
    The occurrence of phenotype switch from an epithelial to a mesenchymal cell state during the activation of the epithelial mesenchymal transition (EMT) program in cancer cells has been closely associ...
    Viviana De Rosa ... Francesca Iommelli
    Published: February 28, 2021 Explor Target Antitumor Ther. 2021;2:36-47
    DOI: https://doi.org/10.37349/etat.2021.00032
    This article belongs to the special issue Liquid Biopsy in Thoracic Cancer
    View:404
    Download:19
    Times Cited: 0
    Open Access
    Review
    Emerging role of pioneer transcription factors in targeted ERα positive breast cancer
    Transcription factors (TFs) are modular protein groups that preferably bind to DNA sequences and guide genomic expression through transcription. Among these key regulators, “pioneer facto...
    Honey Pavithran, Ranjith Kumavath
    Published: February 28, 2021 Explor Target Antitumor Ther. 2021;2:26-35
    DOI: https://doi.org/10.37349/etat.2021.00031
    This article belongs to the special issue Targeting Transcription Factors for Cancer Therapy
    View:625
    Download:21
    Times Cited: 0
    Open Access
    Review
    Old but gold: the role of drug combinations in improving response to immune check-point inhibitors in thoracic malignancies beyond NSCLC
    The introduction of immune checkpoint inhibitors (ICIs) in non-oncogene addicted non-small cell lung cancer (NSCLC) has revolutionized the treatment scenario and led to a meaningful improvement in p...
    Luca Cantini ... Rossana Berardi
    Published: February 28, 2021 Explor Target Antitumor Ther. 2021;2:1-25
    DOI: https://doi.org/10.37349/etat.2021.00030
    This article belongs to the special issue Immunotherapy in Cancer Patients
    View:613
    Download:24
    Times Cited: 0